Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy

CMAJ. Canadian Medical Association Journal

Volumn 175, Issue 7, 2006, Pages 745-748

  Dial, Sandra ^a,b   Delaney, J A Chris ^a,b   Schneider, Verena ^a,b   Suissa, Samy ^a,b  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; VANCOMYCIN; ANTIINFECTIVE AGENT; PROTON PUMP;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CANCER; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE; CONTROLLED STUDY; DRUG USE; ENTERITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; RISK ASSESSMENT; STOMACH ACID SECRETION; TREATMENT OUTCOME; CASE CONTROL STUDY; COMMUNICABLE DISEASE; COMORBIDITY; DRUG ANTAGONISM; FACTUAL DATABASE; MIDDLE AGED; PRESCRIPTION; PSEUDOMEMBRANOUS COLITIS; RISK; RISK FACTOR; STATISTICS; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CLOSTRIDIUM DIFFICILE; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; DATABASES, FACTUAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PRESCRIPTIONS, DRUG; PROTON PUMPS; RISK FACTORS; VANCOMYCIN;

EID: 33749338125     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.060284     Document Type: Article

References (26)

1. Dial S, Delaney JAC, Barkun AN, et al. Use of gastric acid suppressive agents and the risk of community-acquired Clostridium difficile associated disease. JAMA 2005;294:2989-95.
2. Laheij R, Sturkenboom MC, Hassing R, et al. Risk of commuity-acquired pneumonia and use of gastric acid-supressive drugs. JAMA 2004;292:1955-60.
3. Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003;54:243-5.
4. Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004;171(1):33-8.
5. Muto C, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-assodated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273-80.
6. Pathology results and mailbox and mail administrator. In: In Practice Systems Training Services. Version 3 training guide. Available: www.inps.co.uk/vision trainingguide/11v3tgma.pdf (accessed 2006 July 24).
7. NHS connecting for health clinical terminology service. Pathology Bounded Code List (PBCL) of read codes for pathology report messages (version 1.012). Available: www .connectingforhealth.nhs.uk/pathology/tech_standards/docs/bl1012. zip (accessed 2006 July 24).
8. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ 2004;171(1):51-8.
9. Bouza E, Munoz P, Alonso R. Clinical manifestations, treatment and control of infections caused by Clostridium difficile. Clin Microbiol Infect 2005;11(Suppl 4):57-64.
10. Hollowell J. The General Practice Research Database: quality of morbidity data. Popul Trends 1997;87:36-40.
11. Walley T, Mantgani A. The UK general practice research database. Lancet 1997;350:1097-9.
12. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991;302:766-8.
13. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003;23:686-9.
14. Dial S, Delaney JA, Barkun AN, et al. Gastric acid-suppressive agents and risk of Clostridium difficile-associated disease [letter]. JAMA 2006;295:2600-1.
15. Fang FC, Gerding DN, Peterson LR. Diagnosis of Clostridium difficile colitis [letter]. Ann Intern Med 1996;125:515.
16. Simor AE, Yake SL, Tsimidis K. Infection due to Clostridium difficile among elderly residents of a long-term-care facility. Clin Infect Dis 1993;17:672-8.
17. Wilcox MH, Bendall R, Settle CD, et al. Community Clostridium difficile infection [abstract no. L768]. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology; Chicago; 2001. p. 441.
18. Blot E, Escande MC, Besson D, et al. Outbreak of Clostridium difficile-related diarrhoea in an adult oncology unit: risk factors and microbiological characteristics. J Hosp Med 2003;53:187-92.
19. Engel J. Initiatives at the state level and performance characteristics of optimal surveillance systems. Slide presentation presented at Public Workshop on Emerging Clostridial Disease; 2006 May 11; Atlanta. Available: www.fda.gov/cder/meeting /clostridia_disease.htm (accessed 2006 Aug 24).
20. McDonald LC. Surveillance for disease and sources of infection: initiatives at the federal level and international. Slide presentation presented at Public Workshop on Emerging Clostridial Disease; 2006 May 11; Atlanta. Available: www.fda.gov /cder/meeting/clostridia_disease.htm (accessed 2006 Aug 24).
21. Lawrenson R, Williams T, Farmer R. Clinical information for research; the use of general practice databases. J Public Health Med 1999;21:299-304.
22. Jick H, Jick SS, Gurewich V, et al. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-93.
23. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9.
24. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254-60.
25. Kyne L, Sougioultzis S, McFarland LV, et al. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol 2002;23:653-9.
26. Al Tureihi FI, Hassoun A, Wolf-Klein G, et al. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc 2005;6:105-8.